When it comes to vaccinating the world, the simpler the dosing regimen the better. That’s why public-health officials welcomed Johnson & Johnson–Janssen Pharmaceuticals’ one-dose COVID-19 vaccine. The shot is 66% efficacious overall in protecting people from COVID-19 disease, and even more so in preventing the worst outcomes. After concerns were raised over rare blood-clotting side effects, U.S. health officials paused use of the shot in early April but resumed vaccination—with the potential clotting risk listed among the side effects—after determining the benefits outweigh the risks.
More Must-Reads from TIME
- Inside Elon Musk’s War on Washington
- Introducing the 2025 Closers
- Colman Domingo Leads With Radical Love
- Why, Exactly, Is Alcohol So Bad for You?
- The Motivational Trick That Makes You Exercise Harder
- 11 New Books to Read in February
- How to Get Better at Doing Things Alone
- Column: Trump’s Trans Military Ban Betrays Our Troops
